ArticleScientific reports2026
Study on the mechanism of action of HuaZhuoKeLi in modulating LCN2-mediated cellular pyroptosis to ameliorate ulcerative colitis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Ulcerative colitis (UC) is characterized by chronic intestinal inflammation and epithelial barrier dysfunction. Although HuaZhuoKeLi (HZKL) has been clinically used for UC management, its underlying mechanism remains incompletely understood. Lipocalin-2 (LCN2) has been implicated in inflammation-associated cell death, including the NLRP3 inflammasome-mediated pyroptosis. This study aimed to investigate whether HZKL ameliorated UC by modulating LCN2-associated pyroptosis. Integrated bioinformatics analyses were performed using GEO datasets (GSE48959 and GSE75214 as the discovery set; GSE48958 as the validation set). Pyroptosis-related differentially expressed genes (DEGs) were identified using limma and sva normalization, followed by WGCNA to identify UC-associated gene modules. Hub genes were screened via LASSO regression and evaluated by ROC analysis. A dextran sulfate sodium (DSS)-induced UC mouse model was established to assess the effects of HZKL at different doses, using mesalazine as a reference treatment. Drug-containing serum was prepared for in vitro experiments using lipopolysaccharide (LPS)-stimulated Caco-2 cells with LCN2 overexpression or inhibition. Inflammation, pyroptosis, and barrier function were evaluated by histological staining, transmission electron microscopy (TEM), Western blotting, ELISA, qPCR, immunofluorescence, TUNEL assay, CCK-8 assay, and flow cytometry. HZKL notably alleviated colonic inflammation, improved intestinal barrier integrity, and reduced epithelial ultrastructural damage in DSS-induced UC mice. Bioinformatics analyses identified several UC-associated pyroptosis-related genes (LCN2, ZBP1, CD55, and S100A8), all of which exhibited diagnostic potential. Functional experiments demonstrated that HZKL attenuated pyroptosis-related signaling, predominantly accompanied by downregulation of LCN2, reduced inflammatory responses, and enhanced proliferation and migration of intestinal epithelial cells. This study identified LCN2 as a key drug-responsive regulator associated with pyroptosis in UC. HZKL attenuated intestinal inflammation and promoted barrier repair by modulating, at least in part, the LCN2-associated pyroptosis pathway. These findings may provide a mechanistic basis for the therapeutic effects of HZKL, while also highlighting LCN2 as a novel target for further investigation in UC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.